Vuno Valuation
Is A338220 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A338220 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A338220 (₩29500) is trading below our estimate of fair value (₩34728.07)
Significantly Below Fair Value: A338220 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A338220?
Other financial metrics that can be useful for relative valuation.
What is A338220's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₩403.45b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 19.6x |
Enterprise Value/EBITDA | -35.8x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does A338220's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 5.7x | ||
A048870 Synergy Innovation | 2.7x | n/a | ₩229.1b |
A041830 InBodyLtd | 1.7x | 11.4% | ₩318.5b |
A043150 Value Added Technology | 0.9x | 8.4% | ₩346.8b |
A305090 Micro Digital | 17.4x | 29.2% | ₩213.9b |
A338220 Vuno | 20.1x | 43.7% | ₩403.5b |
Price-To-Sales vs Peers: A338220 is expensive based on its Price-To-Sales Ratio (20.1x) compared to the peer average (5.7x).
Price to Earnings Ratio vs Industry
How does A338220's PE Ratio compare vs other companies in the KR Medical Equipment Industry?
Price-To-Sales vs Industry: A338220 is expensive based on its Price-To-Sales Ratio (20.1x) compared to the KR Medical Equipment industry average (2.4x).
Price to Sales Ratio vs Fair Ratio
What is A338220's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 20.1x |
Fair PS Ratio | 28.9x |
Price-To-Sales vs Fair Ratio: A338220 is good value based on its Price-To-Sales Ratio (20.1x) compared to the estimated Fair Price-To-Sales Ratio (28.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.